Skip to main content
OpenTrials
Completed

NCT Number: NCT02485067

Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OAB

The primary purpose of this study is to assess the efficacy and safety of THVD-201(Combination of tolterodine and pilocarpine) in patients with Overactive bladder during the period of treatment, 12 weeks.

This study also includes an open label extension period of an additional 12 weeks following the treatment to assess long-term efficacy and safety of THVD-201 in patients with Overactive bladder.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Inje University Busan Paik Hospital, Busan, South Korea

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 20 - 85 years
  • History of OAB (pure urge or mixed urinary incontinence with predominant urge incontinence) for ≥ 6 months.
  • In the case of females, at least 2 years has passed since menopause. Or all pre-menopausal female subjects must have been using a highly effective method of birth control during the study. Subject of childbearing potential must have had a negative pregnancy test prior to enrollment.

Exclusion criteria

  • Predominate stress incontinence, insensate incontinence (those incapable of distinguishing discrete incontinence episodes) and overflow incontinence, as major reason for urine loss or urinary frequency as determined by the investigator.
  • History of neurogenic bladder.
  • PVR > 200mL
  • History of clinically significant renal disease or estimated creatinine clearance defined by Cockcroft and Gault formula < 30 mL/min.
  • History of malignant tumor within the past 5 years.
  • History or presence of tachyarrhythmia or cardiac disease that in the opinion of the investigator might have confounded the results of the study or posed additional risk to the subject. Subjects who had a value for QTc > 450 msec at the Screening visit.
  • Patient with asthma
  • PSA ≥ 10 ng/mL in male who is 50 years and over.

Treatment and study plan

THVD-201

Drug

Combination of Tolterodine 2mg and Pilocarpine 9mg

Placebo(For THVD-201)

Drug

Detrusitol 2mg tablet

Drug

Tolterodine 2mg

Placebo(For Detrusitol 2mg tablet)

Drug

Primary outcomes

  1. Mean daily micturition frequency

    Time frame: 12 weeks

    The change of Mean daily micturition frequency between 0 and 12 weeks

  2. ADR Incidence of Dry mouth

    Time frame: 12 weeks

Secondary outcomes

  1. Mean daily micturition frequency

    Time frame: 24 weeks

    The change of Mean daily micturition frequency between 0 and 24 weeks

  2. Mean daily Incontinence frequency(12 weeks)

    Time frame: 12 weeks

    The change of Mean daily Incontinence frequency between 0 and 12 weeks

  3. Mean daily Incontinence frequency(24 weeks)

    Time frame: 24 weeks

    The change of Mean daily Incontinence frequency between 0 and 24 weeks

  4. Mean daily Urgency frequency(12 weeks)

    Time frame: 12 weeks

    The change of Mean daily Urgency frequency between 0 and 12 weeks

  5. Mean daily Urgency frequency(24 weeks)

    Time frame: 24 weeks

    The change of Mean daily Urgency frequency between 0 and 24 weeks

  6. Mean daily Nocturia frequency(12 weeks)

    Time frame: 12 weeks

    The change of Mean daily Nocturia frequency between 0 and 12 weeks

  7. Mean daily Nocturia frequency(24 weeks)

    Time frame: 24 weeks

    The change of Mean daily Nocturia frequency between 0 and 24 weeks

  8. Mean daily Micturition volume(12 weeks)

    Time frame: 12 weeks

    The change of Mean daily Micturition volume between 0 and 12 weeks

  9. Mean daily Micturition volume(24 weeks)

    Time frame: 24 weeks

    The change of Mean daily Micturition volume between 0 and 24 weeks

  10. Score of OAB-SS questionnaire(12 weeks)

    Time frame: 12 weeks

    The change of the Score between 0 and 12 weeks

  11. Score of OAB-SS questionnaire(24 weeks)

    Time frame: 24 weeks

    The change of the Score between 0 and 24 weeks

  12. Score of OAB-q questionnaire(12 weeks)

    Time frame: 12 weeks

    The change of the Score between 0 and 12 weeks

  13. Score of OAB-q questionnaire(24 weeks)

    Time frame: 24 weeks

    The change of the Score between 0 and 24 weeks

  14. VAS score of dry mouth symptom(12 weeks)

    Time frame: 12 weeks

    The change of the Score between 0 and 12 weeks

  15. VAS score of dry mouth symptom(24 weeks)

    Time frame: 24 weeks

    The change of the Score between 0 and 24 weeks

  16. Score of Xerostomia Inventory questionnaire(12 weeks)

    Time frame: 12 weeks

    The change of the Score between 0 and 12 weeks

  17. Score of Xerostomia Inventory questionnaire(24 weeks)

    Time frame: 24 weeks

    The change of the Score between 0 and 24 weeks

Sponsors and collaborators

Lead sponsor

SK Chemicals Co., Ltd.

Industry

Registry information

Official study title

Multicenter, Randomized, Double-blind, Parallel, Active Control, Phase III Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With Overactive Bladder Including an Open-label, Extension Study

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Jun 30, 2015
Registry last updated
Jan 12, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.